A Single-centre Study of Certican (Everolimus) as Prophylaxis for Graft-versus-Host Disease Following Post-Transplantation Cyclophosphamide After Allogeneic Stem Cell Transplantation
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Everolimus (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Acronyms OCTET-Ever
- 19 Jul 2024 Results for safety published in the European Journal of Haematology
- 16 Mar 2021 Status changed from active, no longer recruiting to completed.
- 26 Nov 2020 Planned End Date changed from 1 Jun 2019 to 1 Dec 2020.